JP2020508329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020508329A5 JP2020508329A5 JP2019546144A JP2019546144A JP2020508329A5 JP 2020508329 A5 JP2020508329 A5 JP 2020508329A5 JP 2019546144 A JP2019546144 A JP 2019546144A JP 2019546144 A JP2019546144 A JP 2019546144A JP 2020508329 A5 JP2020508329 A5 JP 2020508329A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- tim3
- cd40l
- domain
- ox40l
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022130749A JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762464002P | 2017-02-27 | 2017-02-27 | |
| US62/464,002 | 2017-02-27 | ||
| PCT/US2018/020040 WO2018157165A1 (en) | 2017-02-27 | 2018-02-27 | Methods of making and using extracellular domain-based chimeric proteins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022130749A Division JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020508329A JP2020508329A (ja) | 2020-03-19 |
| JP2020508329A5 true JP2020508329A5 (enExample) | 2021-04-08 |
| JP7128195B2 JP7128195B2 (ja) | 2022-08-30 |
Family
ID=63253416
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546144A Expired - Fee Related JP7128195B2 (ja) | 2017-02-27 | 2018-02-27 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2019546149A Active JP7260477B2 (ja) | 2017-02-27 | 2018-02-27 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2022130749A Pending JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2023062366A Active JP7620045B2 (ja) | 2017-02-27 | 2023-04-06 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2025003769A Withdrawn JP2025061180A (ja) | 2017-02-27 | 2025-01-09 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019546149A Active JP7260477B2 (ja) | 2017-02-27 | 2018-02-27 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2022130749A Pending JP2022159510A (ja) | 2017-02-27 | 2022-08-18 | 細胞外ドメインベースのキメラタンパク質の製造方法及び使用方法 |
| JP2023062366A Active JP7620045B2 (ja) | 2017-02-27 | 2023-04-06 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
| JP2025003769A Withdrawn JP2025061180A (ja) | 2017-02-27 | 2025-01-09 | Ｔｉｇｉｔ及びｌｉｇｈｔベースのキメラタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US11332509B2 (enExample) |
| EP (2) | EP3585425A4 (enExample) |
| JP (5) | JP7128195B2 (enExample) |
| KR (1) | KR102745835B1 (enExample) |
| CN (3) | CN118994414A (enExample) |
| AU (2) | AU2018223821B2 (enExample) |
| BR (1) | BR112019017298A2 (enExample) |
| CA (2) | CA3054127A1 (enExample) |
| IL (2) | IL268198B2 (enExample) |
| MX (1) | MX2019009812A (enExample) |
| MY (1) | MY207687A (enExample) |
| PH (1) | PH12019501533A1 (enExample) |
| SG (1) | SG11201906465YA (enExample) |
| WO (2) | WO2018157162A1 (enExample) |
| ZA (1) | ZA201905488B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL268198B2 (en) | 2017-02-27 | 2024-10-01 | Shattuck Labs Inc | Tigit- and light-based chimeric proteins |
| US12134790B2 (en) | 2017-09-27 | 2024-11-05 | Inozyme Pharma, Inc. | Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1) |
| CN112566650A (zh) * | 2018-06-21 | 2021-03-26 | 沙塔克实验室有限公司 | 异二聚体蛋白及其用途 |
| MX2021002292A (es) | 2018-08-29 | 2021-05-27 | Shattuck Labs Inc | Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa. |
| AU2019328305A1 (en) * | 2018-08-29 | 2021-03-04 | Shattuck Labs, Inc. | Combination therapies comprising tim-3-based chimeric proteins |
| US20210324041A1 (en) * | 2018-08-29 | 2021-10-21 | Shattuck Labs, Inc. | Combination therapies |
| EP3844280A4 (en) * | 2018-08-31 | 2022-09-14 | Yale University | ENPP1 POLYPEPTIDES AND METHODS OF USE |
| CA3112788A1 (en) * | 2018-09-05 | 2020-03-12 | Arizona Board Of Regents On Behalf Of Arizona State University | Oncolytic virus platform to treat hematological cancer |
| IL283165B2 (en) | 2018-11-21 | 2024-12-01 | Mayo Found Medical Education & Res | Adenoviruses and methods for using adenoviruses |
| CN113747947A (zh) * | 2019-02-28 | 2021-12-03 | 沙塔克实验室有限公司 | 组合疗法 |
| MX2021010577A (es) * | 2019-04-29 | 2021-10-13 | Mayo Found Medical Education & Res | Compuestos de union a pd-l1 multivalentes para tratar cancer. |
| CN112111437B (zh) * | 2020-05-25 | 2023-09-05 | 江南大学 | 2’-岩藻糖基乳糖产量提高的重组枯草芽孢杆菌及其构建方法 |
| TW202210514A (zh) * | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| EP4162036A1 (en) | 2020-06-09 | 2023-04-12 | Inozyme Pharma, Inc. | Soluble enpp1 or enpp3 proteins and uses thereof |
| WO2021257124A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| CN111808800B (zh) * | 2020-07-20 | 2022-08-26 | 中南大学湘雅二医院 | 一种体外诱导免疫抑制性髓系抑制细胞及其制备和应用 |
| IL301454A (en) * | 2020-09-17 | 2023-05-01 | Shattuck Labs Inc | Clinical dosing of SIRP1A chimeric protein |
| EP4237000A4 (en) * | 2020-11-02 | 2024-09-18 | Athae Bio, Inc. | TWO-DOMAIN MULTIMERIC FUSION PROTEINS |
| AU2021390545A1 (en) * | 2020-12-03 | 2023-07-06 | Shattuck Labs, Inc. | Methods of treating cancer using tigit-and light-based chimeric proteins |
| CN116897202A (zh) * | 2021-02-24 | 2023-10-17 | 科济生物医药（上海）有限公司 | Tigit工程化细胞及其组合物 |
| CN115260312B (zh) * | 2021-04-30 | 2025-02-14 | 保诺科技（北京）有限公司 | 结合ox40的抗体或抗原结合片段 |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
| CN115960247A (zh) * | 2021-10-13 | 2023-04-14 | 苏州科锐迈德生物医药科技有限公司 | 基于t7rna聚合酶的融合多肽及其制备方法、用途 |
| WO2023077156A1 (en) * | 2021-11-01 | 2023-05-04 | Shattuck Labs, Inc. | Modified mrna therapeutics |
| CN114209815B (zh) * | 2021-11-22 | 2024-04-26 | 山东大学 | 一种药物组合物及其制备方法和应用 |
| WO2023105281A1 (en) * | 2021-12-11 | 2023-06-15 | Fundaciò Privada Institut De Recerca De La Sida-Caixa | Soluble tigit recombinant proteins |
| CN115490771B (zh) * | 2021-12-24 | 2026-04-28 | 合肥天港免疫药物有限公司 | 重组抗体及其应用 |
| CN114196691B (zh) * | 2021-12-28 | 2023-08-11 | 重庆澳龙生物制品有限公司 | 一种制备防治牛、羊棘球蚴病多表位重组疫苗的基因、蛋白质、疫苗和应用 |
| JP2025523387A (ja) | 2022-06-07 | 2025-07-23 | ジェネンテック， インコーポレイテッド | 抗ｐｄ－ｌ１アンタゴニストおよび抗ｔｉｇｉｔアンタゴニスト抗体を含む、肺がん治療の有効性を判定するための方法 |
| CN117624375A (zh) * | 2022-08-30 | 2024-03-01 | 北京卡替医疗技术有限公司 | 增强受体、表达增强受体的免疫细胞及其用途 |
| CN116350748A (zh) * | 2022-11-01 | 2023-06-30 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | Tigit融合蛋白在制备用于治疗系统性红斑狼疮药物中的应用 |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| CN116041542B (zh) * | 2022-12-06 | 2026-02-17 | 上海恩凯细胞技术有限公司 | 逆转肿瘤微环境抑制性信号的nk细胞制备方法及应用 |
| CN116037072B (zh) * | 2023-02-24 | 2025-01-03 | 宁夏医科大学 | 一种血清抗体亲和分离材料的制备方法与应用 |
| CN116925236B (zh) * | 2023-05-12 | 2024-06-04 | 上海恩凯细胞技术有限公司 | 嵌合转换受体及其应用 |
| AU2024314312A1 (en) * | 2023-06-22 | 2025-10-30 | Fbd Biologics Limited | Multi-targeting protein complex and methods of use thereof |
| CN116982600B (zh) * | 2023-09-14 | 2025-11-18 | 江苏集萃药康生物科技股份有限公司 | 一种cd69人源化小鼠模型的构建方法及其应用 |
| CN119930791A (zh) * | 2023-11-02 | 2025-05-06 | 重庆精准生物技术有限公司 | 特异性tigit肽段 |
| CN122295374A (zh) * | 2023-12-29 | 2026-06-26 | 沈阳三生制药有限责任公司 | 一种tigit多肽及tigit/ctla4融合蛋白 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| DK0897983T3 (da) | 1991-10-25 | 2003-08-11 | Immunex Corp | Antistoffer mod CD40-L |
| EP1908780B1 (en) | 2000-01-03 | 2012-08-15 | The Trustees Of The University Of Pennsylvania | Novel chimeric proteins and methods for using the same |
| US20110041190A1 (en) | 2002-10-31 | 2011-02-17 | Tykocinski Mark L | Novel chimeric proteins |
| US7696168B2 (en) * | 2000-04-21 | 2010-04-13 | Tufts Medical Center, Inc. | G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same |
| EP1456652A4 (en) | 2001-11-13 | 2005-11-02 | Dana Farber Cancer Inst Inc | IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR |
| JP2008500013A (ja) | 2003-10-03 | 2008-01-10 | ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド | Ｔｉｍ−３ポリペプチド |
| BRPI0406605B8 (pt) | 2003-11-13 | 2021-05-25 | Hanmi Holdings Co Ltd | conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo |
| JP2006345852A (ja) | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
| WO2007133811A2 (en) | 2006-05-15 | 2007-11-22 | Viral Logic Systems Technology Corp. | Cd47 related compositions and methods for treating immunological diseases and disorders |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CA2656923A1 (en) | 2006-06-21 | 2007-12-27 | Genentech, Inc. | Crystal structures of ox40l and ox40l complexed with ox40 receptor |
| US20100150931A1 (en) | 2006-11-22 | 2010-06-17 | Centre Hospitalier De L'universite De Montreal | Novel receptor for cd40l and uses thereof |
| WO2008144029A1 (en) | 2007-05-14 | 2008-11-27 | The University Of Chicago | Antibody-light fusion products for cancer therapeutics |
| PT3056515T (pt) | 2008-01-15 | 2019-07-19 | Univ Leland Stanford Junior | Métodos para manipulação da fagocitose mediada por cd47 |
| US20090226435A1 (en) | 2008-03-08 | 2009-09-10 | Sanjay Khare | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| EP2111869A1 (en) | 2008-04-23 | 2009-10-28 | Stichting Sanquin Bloedvoorziening | Compositions and methods to enhance the immune system |
| CN102137869B (zh) | 2008-06-30 | 2018-07-06 | 宾夕法尼亚大学 | Fn14/TRAIL融合蛋白 |
| JP2011526794A (ja) | 2008-07-02 | 2011-10-20 | エマージェント プロダクト デベロップメント シアトル， エルエルシー | ＴＧＦ−βアンタゴニスト多重標的結合性分子 |
| PL2604693T3 (pl) | 2008-07-21 | 2016-09-30 | Jednołańcuchowe cząsteczki TNFSF | |
| US8183207B2 (en) | 2008-11-26 | 2012-05-22 | Five Prime Therapeutics, Inc. | Treatment of osteolytic disorders and cancer using CSF1R extracellular domain fusion molecules |
| US8080246B2 (en) | 2008-11-26 | 2011-12-20 | Five Prime Therapeutics, Inc. | Colony stimulating factor 1 receptor (CSF1R) extracellular domain fusion molecules |
| BRPI0923442A2 (pt) | 2008-12-19 | 2016-01-12 | Novartis Ag | polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios. |
| US9221895B2 (en) | 2009-03-13 | 2015-12-29 | The Trustees Of The University Of Pennsylvania | OX40/TRAIL fusion proteins |
| US8993524B2 (en) | 2010-03-05 | 2015-03-31 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| EP2621514B1 (en) | 2010-09-28 | 2016-09-21 | KAHR Medical (2005) Ltd | Compositions and methods for treatment of hematological malignancies |
| CN103261217B (zh) | 2010-11-11 | 2017-04-26 | 港大科桥有限公司 | 可溶性 pd‑1变体、融合构建体及其用途 |
| EP3415528B1 (en) | 2011-04-13 | 2021-05-26 | Bristol-Myers Squibb Company | Fc fusion proteins comprising novel linkers or arrangements |
| WO2012162565A2 (en) | 2011-05-25 | 2012-11-29 | Cel-Sci Corporation | Method for inducing an immune response for treatment of cancer and autoimmune diseases or conditions |
| CN102850458B (zh) | 2011-06-28 | 2014-10-01 | 华博生物医药技术（上海）有限公司 | 新型重组双功能融合蛋白及其制法和用途 |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| US9828432B2 (en) | 2012-02-06 | 2017-11-28 | Providence Health & Services—Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| PL3489254T3 (pl) | 2012-04-30 | 2023-01-30 | Biocon Limited | Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania |
| EP2850106B1 (en) | 2012-05-18 | 2022-03-23 | Aptevo Research and Development LLC | Bispecific scfv immunofusion (bif) binding to cd123 and cd3 |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| ME03550B (me) | 2012-12-17 | 2020-07-20 | Trillium Therapeutics Inc | Lečenje cd47+ obolelih ćelija sa sirp alfa-fc fuzijama |
| EP2941438A1 (en) | 2013-01-01 | 2015-11-11 | Kahr Medical Ltd. | Stable form of signal converting protein fusion proteins, and methods of use and preparation thereof |
| EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
| WO2014121093A1 (en) | 2013-01-31 | 2014-08-07 | Thomas Jefferson University | Fusion proteins that facilitate cancer cell destruction |
| WO2015116178A1 (en) | 2014-01-31 | 2015-08-06 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector t cells |
| EP2951199A4 (en) | 2013-01-31 | 2016-07-20 | Univ Jefferson | Fusion proteins for the modulation of regulatory and effector T cells |
| EP2951209A4 (en) | 2013-01-31 | 2016-06-22 | Univ Jefferson | CD40 OX40 AGONIST FUSION PROTEIN AND USES THEREOF |
| EP2950814A4 (en) | 2013-01-31 | 2016-06-08 | Univ Jefferson | FUSION PROTEINS BASED ON PD-L1 AND PD-L2 AND USES THEREOF |
| IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
| MY186864A (en) | 2013-03-12 | 2021-08-26 | Biocon Ltd | Fusion immunomodulatory proteins and methods for making same |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| US10144770B2 (en) * | 2013-10-17 | 2018-12-04 | National University Of Singapore | Chimeric receptors and uses thereof in immune therapy |
| US10196435B2 (en) | 2013-11-18 | 2019-02-05 | University Of Southern California | OX40L fusion protein for the immunotherapy of tumors of veterinary animals |
| MX2016007965A (es) | 2013-12-17 | 2016-10-28 | Genentech Inc | Terapia de combinacion que comprende agonistas de union a ox40 y antagonistas de union al eje pd-1. |
| AU2015205530B8 (en) | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| JP2017504327A (ja) | 2014-01-14 | 2017-02-09 | カイマブ・リミテッド | 抗ｌｉｇｈｔ抗体 |
| WO2015112534A2 (en) | 2014-01-21 | 2015-07-30 | Medimmune, Llc | Compositions and methods for modulating and redirecting immune responses |
| JP6355032B2 (ja) | 2014-03-24 | 2018-07-11 | イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド | 新規組換え二機能性融合タンパク質、それらの調製および使用 |
| CN106456734A (zh) | 2014-05-29 | 2017-02-22 | 免疫医疗有限责任公司 | Ox40l融合蛋白及其用途 |
| EP3160497A4 (en) | 2014-06-27 | 2018-01-17 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
| WO2016023040A1 (en) | 2014-08-08 | 2016-02-11 | Alexo Therapeutics International | Sirp-alpha variant constructs and uses thereof |
| JP6640834B2 (ja) | 2014-08-11 | 2020-02-05 | デリニア， インコーポレイテッド | 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体 |
| ES2751915T5 (es) | 2014-08-15 | 2022-12-23 | Merck Patent Gmbh | Proteínas de fusión de inmunoglobulina con SIRP alfa |
| CN106999583A (zh) | 2014-11-17 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法 |
| MX2017007136A (es) | 2014-12-05 | 2017-12-04 | Immunext Inc | Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8. |
| WO2016112983A1 (en) * | 2015-01-15 | 2016-07-21 | Biontech Ag | Cytokine fusion proteins |
| WO2016126608A1 (en) | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| MA41460A (fr) | 2015-02-03 | 2017-12-12 | Oncomed Pharm Inc | Agents de liaison à la tnfrsf et leurs utilisations |
| US10046047B2 (en) | 2015-02-06 | 2018-08-14 | Heat Biologics, Inc. | Vector co-expressing vaccine and costimulatory molecules |
| WO2016166139A1 (en) | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
| DK3298043T3 (da) | 2015-05-18 | 2021-02-15 | Ab Initio Biotherapeutics Inc | SIRP-polypeptidsammensætninger og fremgangsmåder til anvendelse |
| RU2740672C2 (ru) | 2015-08-07 | 2021-01-19 | ЭйЭлЭкс Онколоджи Инк. | Конструкции, имеющие sirp-альфа домен или его вариант |
| SG10201913573UA (en) | 2015-10-01 | 2020-03-30 | Heat Biologics Inc | Compositions and methods for adjoining type i and type ii extracellular domains as heterologous chimeric proteins |
| EP3529276A4 (en) | 2016-10-21 | 2020-06-17 | Arch Oncology, Inc. | CD47 THERAPEUTIC ANTIBODIES |
| IL268198B2 (en) | 2017-02-27 | 2024-10-01 | Shattuck Labs Inc | Tigit- and light-based chimeric proteins |
-
2018
- 2018-02-27 IL IL268198A patent/IL268198B2/en unknown
- 2018-02-27 JP JP2019546144A patent/JP7128195B2/ja not_active Expired - Fee Related
- 2018-02-27 US US16/484,852 patent/US11332509B2/en active Active
- 2018-02-27 AU AU2018223821A patent/AU2018223821B2/en active Active
- 2018-02-27 CN CN202410811167.XA patent/CN118994414A/zh active Pending
- 2018-02-27 BR BR112019017298-0A patent/BR112019017298A2/pt active Search and Examination
- 2018-02-27 US US16/484,850 patent/US20190367579A1/en not_active Abandoned
- 2018-02-27 MY MYPI2019004825A patent/MY207687A/en unknown
- 2018-02-27 CN CN201880009524.3A patent/CN110234345A/zh active Pending
- 2018-02-27 CA CA3054127A patent/CA3054127A1/en active Pending
- 2018-02-27 WO PCT/US2018/020037 patent/WO2018157162A1/en not_active Ceased
- 2018-02-27 KR KR1020197023430A patent/KR102745835B1/ko active Active
- 2018-02-27 EP EP18757341.5A patent/EP3585425A4/en not_active Withdrawn
- 2018-02-27 MX MX2019009812A patent/MX2019009812A/es unknown
- 2018-02-27 JP JP2019546149A patent/JP7260477B2/ja active Active
- 2018-02-27 SG SG11201906465YA patent/SG11201906465YA/en unknown
- 2018-02-27 EP EP18756868.8A patent/EP3585418A4/en not_active Withdrawn
- 2018-02-27 CN CN201880013956.1A patent/CN110381983B/zh active Active
- 2018-02-27 IL IL313003A patent/IL313003A/en unknown
- 2018-02-27 CA CA3054133A patent/CA3054133A1/en active Pending
- 2018-02-27 WO PCT/US2018/020040 patent/WO2018157165A1/en not_active Ceased
-
2019
- 2019-06-28 PH PH12019501533A patent/PH12019501533A1/en unknown
- 2019-08-20 ZA ZA2019/05488A patent/ZA201905488B/en unknown
-
2020
- 2020-04-24 US US16/857,787 patent/US10899817B2/en active Active
- 2020-09-10 US US17/017,108 patent/US10927159B2/en active Active
-
2022
- 2022-04-06 US US17/714,912 patent/US20220227831A1/en not_active Abandoned
- 2022-04-11 US US17/717,740 patent/US12071465B2/en active Active
- 2022-08-18 JP JP2022130749A patent/JP2022159510A/ja active Pending
- 2022-08-18 AU AU2022218575A patent/AU2022218575A1/en not_active Abandoned
-
2023
- 2023-04-06 JP JP2023062366A patent/JP7620045B2/ja active Active
-
2024
- 2024-03-04 US US18/594,400 patent/US20240190939A1/en not_active Abandoned
- 2024-07-17 US US18/775,288 patent/US20240368242A1/en active Pending
-
2025
- 2025-01-09 JP JP2025003769A patent/JP2025061180A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020508068A5 (enExample) | ||
| JP7829773B2 (ja) | Ｉｌ２７受容体結合に関連する組成物および方法 | |
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| JP2018529363A5 (enExample) | ||
| US20160347814A1 (en) | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases | |
| KR20210013160A (ko) | 다중-특이적 결합 단백질 및 그에 대한 개선 | |
| JP6242484B2 (ja) | 特定の改善されたヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| JP2018521008A (ja) | 腫瘍形成を処置するための治療用組成物および治療方法 | |
| RU2018107047A (ru) | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения | |
| HK1259190A1 (zh) | 嵌合抗原受体相关的方法和组合物 | |
| TW201008580A (en) | Dual variable domain immunoglobulin and uses thereof | |
| TW201006485A (en) | Dual variable domain immunoglobulins and uses thereof | |
| TW201109438A (en) | Dual variable domain immunoglobulins and uses thereof | |
| JP2022512541A (ja) | Ｐｄ－１系キメラタンパク質を含む併用療法 | |
| CN103282380A (zh) | 红细胞结合性治疗剂 | |
| JP6154895B2 (ja) | ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子 | |
| TW200922616A (en) | FOXM1 peptide and medicinal agent comprising the same | |
| JP2020508063A5 (enExample) | ||
| CA3044424C (en) | Fractal combination therapy | |
| JP6933724B2 (ja) | Ｎｋ細胞活性化融合タンパク質、ｎｋ細胞およびそれらを含む医薬組成物 | |
| CN103965363A (zh) | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 | |
| IL282193B2 (en) | Nk engager molecules and methods of use thereof | |
| CN102725311A (zh) | 治疗发炎的方法 | |
| CN112125975A (zh) | Pd-l1和cd47双特异性融合蛋白及其医药用途 | |
| CN115023435B (zh) | 免疫治疗化合物和方法 |